07 Kadcyla by Roche
Nivolumab by Bristol-Myers Squibb Co .
top 10
07 Kadcyla by Roche
Roche ’ s ( SIX : RO , roG ; OTCQX : RHHBY ) Kadcyla is the third HER2-targeted mAb drug from the company for the second-line treatment of metastatic HER2-positive breast cancer . Kadcyla can extend life by six months longer than the next best treatment . According to Roche , Kadcyla took 15 years to develop . It is already routinely available in several European countries .
06
Nivolumab by Bristol-Myers Squibb Co .
Bristol-Myers Squibb ’ s ( NYSE : BMY ) new drug helped skin cancer patients live longer than those who received chemotherapy in a clinical trial . Roughly 73 percent of melanoma patients receiving nivolumab were still alive one year later after the start of treatment . Bristol-Myers has applied for U . S . Food and Drug Administration approval of nivolumab as a treatment for melanoma , and expects a decision by March 2015 .
www . roche . com www . bms . com
26 January 2015